Hodgkins Lymphoma Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
10-064-B Molecular characterization of hematopoietic malignancies
Select
10-406-A CALGB 50801: Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
10-558-B Long Term Database Collection for Lymphoma
Select
12-0056 NU11H01 A Phase II Trial of Sequential SGN35 Therapy With Adriamycin, Vinblastine, and Dacarbazine SAVD for Older Patients with Untreated Hodgkin Lymphoma
Select
13-0119 CALGB 51101: A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy For Newly Dianosed Primary CNS B-Cell Lymphoma
Select
IRB13-1105 NCI 9426: A Phase I Study of Ibrutinib (PCI-32765) in Combination with Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
IRB13-1297 Lymphoma Program Biobank
Select
IRB13-1406 Prospective, Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-cell Lymphomas
Select
IRB13-1413 A Phase I/II Trial of Brentuximab Vedotin plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0655 A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies
Select
IRB14-1120 Multicenter Phase II Study of the Bendamustine, Obinutuzumab, and Dexamethasone (BOD) Regimen in Un-Fit Elderly = 70 Years of Age Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL) Patients
Select
IRB14-1042 A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Select
IRB14-1370 A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Select
IRB15-0091 An Open-label, Dose-escalation/expansion, Phase 1 Study of ASP4132, Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma
Select
IRB15-0368 A Phase II Clinical Trial of MK-3475 (pembrolizumab) in Subjects with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
Select
IRB15-0459 An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Select
IRB15-0608 A Multi-Center Open-Label Study of the Brutonís Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas
Select
IRB15-0835 A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team